# AIM ImmunoTech (AIM) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/AIM
## Company Profile
- Ticker: AIM
- Exchange: AMEX
- Sector: Biotechnology
- Location: United States
- Tags: Biopharma, Novel Therapies, Immunotherapy
## Stock Data
- Close: 0.257 USD
- Market cap: 7845961.334999999 USD
- Last updated: 2026-07-17
## Business Overview
AIM ImmunoTech is an immunology-oriented biopharmaceutical company focused on inflammatory and immune-mediated disease programs, where each new data point can reshape expectations for the pipeline and the next catalyst window.
## Why The Stock Is Moving

AIM is trading with a steady catalyst profile while investors wait for the next headline that changes the story.

## Geographic Base

Headquartered in the United States and listed on 美国证券交易所, AIM ImmunoTech is followed within the immunology universe for its exposure to chronic-disease treatment demand and catalyst-driven clinical updates.

## Business Model

AIM ImmunoTech is a pipeline-led immunology story, so the market tends to track readouts, regulatory milestones, and how the company expands from one immune program to the next.

## Landscape Position

Compared with more mature peers, AIM ImmunoTech sits close to the development side of the biotech landscape, where immunology data can change sentiment quickly.

## Recent News
- 2026-07-20 10:59 EST — [Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-eb3e7bda) — Source: BMYBristol-Myers Squibb Company
- 2026-07-20 07:00 EST — [European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds](https://biopharmsignal.com/news/GSK/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose--8906d096) — Source: GSK plc
- 2026-07-17 09:00 EST — [GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)](https://biopharmsignal.com/news/GSK/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in--0e112206) — Source: GSK plc
- 2026-07-16 12:31 EST — [Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia](https://biopharmsignal.com/news/MRK/merck-s-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibit-1b899588) — Source: Merck
- 2026-07-16 12:00 EST — [Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-conference-call-discussing-second-quarter-2026-financial-resu-458d7635) — Source: Alnylam Pharmaceuticals, Inc.